CONMED (CNMD) Jefferies London Healthcare Conference 2024 summary

Leadership transition and strategic priorities

• Incoming CEO plans to spend the first 100 days listening to employees, customers, and investors before making changes, while maintaining a focus on growth.

• Emphasis on continuing the company's growth trajectory, leveraging experience from previous leadership.

• No immediate major changes expected, but fresh perspectives will be brought to the business.

M&A strategy and financial discipline

• Focus remains on minimally invasive surgery and orthopedics, with ongoing evaluation of innovative, accretive technologies.

• M&A decisions are not strictly tied to leverage ratios but to strategic fit, growth, and shareholder value.

• Acquisition targets must offer protection through know-how or IP and deliver value to shareholders.

• The company cycles leverage up with acquisitions and brings it down through organic growth before new deals.

AirSeal business and competitive landscape

• AirSeal has not seen negative impact from new robotic competitors; growth remains strong, especially in non-robotic procedures.

• Sales teams are shifting focus to laparoscopy in the U.S. and expanding robotic sales internationally.

• Non-robotic AirSeal sales are growing faster than robotic, with longer sales cycles but larger potential deals.

• AirSeal is most valued in longer, complex procedures, with consistent usage patterns post-competition launch.